<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3553">
  <stage>Registered</stage>
  <submitdate>21/05/2012</submitdate>
  <approvaldate>21/05/2012</approvaldate>
  <nctid>NCT01604408</nctid>
  <trial_identification>
    <studytitle>A Study in Older Participants Who Have Fallen and Have Muscle Weakness</studytitle>
    <scientifictitle>A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>I1Q-MC-JDDJ</secondaryid>
    <secondaryid>14499</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Muscle Weakness</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - LY2495655
Treatment: drugs - Placebo

Experimental: LY2495655 - 315 mg administered as three Subcutaneous (SQ) injections every 4 weeks for 20 weeks

Placebo Comparator: Placebo - Administered as three SQ injections every 4 weeks for 20 weeks


Other interventions: LY2495655
Administered SQ

Treatment: drugs: Placebo
Administered SQ

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from Baseline to 24 week endpoint in appendicular Lean Body Mass (aLBM)</outcome>
      <timepoint>Baseline, 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Stair Climbing (StC) Score</outcome>
      <timepoint>Baseline, 12 weeks, 24 weeks, 36 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Repeated Chair Stands (RCS) Score</outcome>
      <timepoint>Baseline, 12 weeks, 24 weeks, 36 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Usual Gait Speed (uGS) at 4 Meters</outcome>
      <timepoint>Baseline, 12 weeks, 24 weeks, 36 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Sustained at least 1 fall within 1 calendar year before study screening.

          -  Requires =12 seconds to perform a repeated chair stands test or is unable to complete
             this test at screening.

          -  Hand grip strength is =37 kilograms (kg) for men (81.4 pounds) or =21 kg for women
             (46.2 pounds) at screening.

          -  Can stand up from a chair and walk =10 meters without human assistance (gait aids are
             acceptable such as cane[s], crutches, or walker) at screening.

          -  Able to climb at least 1 step on a staircase without human assistance according to the
             participant at screening (using handrails is allowed).

          -  Have screening clinical laboratory test results within normal reference range for the
             population, or have results with acceptable deviations that are judged to be not
             clinically significant by the investigator.</inclusivecriteria>
    <inclusiveminage>75</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Major lower limb pain or neurologic impairment or vestibular vertigo or visual
             impairment that could severely confound measures of physical performance.

          -  Recent lower limb fracture and/or major lower limb surgery.

          -  Planned major surgical procedure within 6 months following study drug dosing.

          -  Have had a lower extremity amputation of the foot, leg, and/or thigh.

          -  Have a body mass index (BMI) =35 kg/m2.

          -  Severe vitamin D deficiency.

          -  Underlying muscle disease other than age-associated muscle waste or disuse atrophy.

          -  Current use or previous use of any drugs known to influence muscle mass or
             performance.

          -  Have had a recent neurologic injury (&lt;6 months before study drug dosing) such as
             stroke or spinal cord injury.

          -  History of a malignant neoplasm in the 18 months before first study drug dosing.

          -  Have a history or presence of unstable cardiovascular or pulmonary comorbidities.

          -  Have a positive fecal occult blood (FOB) test at screening or the participant cannot
             provide a stool sample for FOB testing before first study drug dosing.

          -  Have either severe ongoing liver disease or aspartate aminotransferase (AST) or
             alanine aminotransferase (ALT) &gt;2 times upper limit of normal (ULN), or alkaline
             phosphatase (ALP) &gt;1.5 times ULN, or total bilirubin &gt;1.5 times ULN at screening.

          -  Have an estimated creatinine clearance &lt;20 mL/minute.

          -  Have a history of severe allergic reaction to a monoclonal antibody.

          -  Are males with a female partner of childbearing potential who do not agree to use
             contraception during the treatment period of the study and up to 15 weeks after the
             last dose of investigational product (study drug).

          -  Have known allergies to LY2495655, its constituents, or related compounds.

          -  Have severe active psychiatric disease or cognitive impairment Mini-Mental State
             Examination ([MMSE] &lt;24) making the participant unlikely to understand the informed
             consent form or comply with protocol procedures.

          -  Excessive consumption of alcohol or abuse of drugs.

          -  Have uncontrolled diabetes mellitus.

          -  Have had ocular trauma, ophthalmologic surgery, or eye laser treatment within 6 months
             before study drug dosing.

          -  Have hyponatremia (serum sodium levels &lt;135 millimoles/Liter (mmol/L) at screening
             unless a retest shows normonatremia before study drug dosing.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>172</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Hornsby</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kingswood</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Daw Park</hospital>
    <postcode>2077 - Hornsby</postcode>
    <postcode>2747 - Kingswood</postcode>
    <postcode>5041 - Daw Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Caba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Stuttgart</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Huddinge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Mölndal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>LY2495655 is an investigational drug being tested for muscle wasting. Muscle wasting includes
      shrinking of the muscle and weakness. This can occur when a muscle is no longer as active as
      usual. When muscles are no longer in use, they become weaker.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01604408</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>